FindTrial
Sign In

Cilta-cel

DRUG8 trials

Sponsors

Janssen Research & Development, LLC, Stichting European Myeloma Network, Janssen Scientific Affairs, LLC

Conditions

Multiple Myeloma

Phase 2

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
CompletedNCT05347485
Janssen Scientific Affairs, LLCMultiple Myeloma
Start: 2022-05-13End: 2023-12-15Updated: 2025-04-25
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Active, not recruitingNCT06550895
Janssen Research & Development, LLCMultiple Myeloma
Start: 2024-09-16End: 2027-08-26Updated: 2026-03-13
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Active, not recruitingNCT06577025
Janssen Research & Development, LLCMultiple Myeloma
Start: 2024-08-20End: 2030-09-02Updated: 2026-03-13
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RecruitingNCT07149857
Janssen Research & Development, LLCMultiple Myeloma
Start: 2025-10-03End: 2029-04-06Target: 60Updated: 2026-03-13

Phase 3

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Active, not recruitingNCT04181827
Janssen Research & Development, LLCMultiple Myeloma
Start: 2020-06-12End: 2029-04-09Updated: 2026-03-16
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Active, not recruitingNCT04923893
Janssen Research & Development, LLCMultiple Myeloma
Start: 2021-08-19End: 2036-09-22Updated: 2026-03-13
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Active, not recruitingNCT05257083
Stichting European Myeloma NetworkMultiple Myeloma
Start: 2023-10-10End: 2040-08-01Updated: 2026-03-17

Phase 4

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingNCT05201781
Janssen Research & Development, LLCMultiple Myeloma
Start: 2022-03-09End: 2037-10-30Target: 295Updated: 2026-03-23

Related Papers

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
2026-01-07
Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study
Blood2025-11-03
Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma
Blood2025-11-03
Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop)
Blood2025-11-03
Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison
Blood2025-11-03
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
2025-08-06
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.
2025-07-04
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology2025-05-285 citations
Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses.
Journal of Clinical Oncology2025-05-282 citations
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
New England Journal of Medicine2025-02-1233 citations
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
2025-01-018 citations
Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Blood2024-11-059 citations
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
Frontiers in Immunology2024-08-215 citations
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting
Journal of Comparative Effectiveness Research2024-08-208 citations
Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology2024-08-072 citations
Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
Journal of Clinical Oncology2024-06-019 citations
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
2024-04-2462 citations
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma
Blood2023-11-0291 citations
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial
Blood2023-11-024 citations
Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy
Blood2023-11-024 citations

19 more papers not shown